• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

    10/22/24 7:00:14 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SWTX alert in real time by email

    STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates.

    To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company's website at https://ir.springworkstx.com.

    About SpringWorks Therapeutics

    SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.

    For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

    Contacts:

    Investors

    [email protected]

    Media

    [email protected]



    Primary Logo

    Get the next $SWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What is the main purpose of the conference call and webcast scheduled for November 12, 2024?

      SpringWorks Therapeutics is hosting a live conference call and webcast to report its third quarter financial results.

    • When is SpringWorks' conference call scheduled?

      The conference call will take place at 8:30 a.m. ET on Tuesday, November 12, 2024.

    • How can individuals participate in the conference call?

      Interested participants can join the conference call by either pre-registering for phone access or attending the live webcast through the provided link.

    • What is one significant achievement of SpringWorks Therapeutics mentioned in the announcement?

      SpringWorks Therapeutics has its first FDA-approved therapy, OGSIVEO® (nirogacestat), which treats adult patients with progressing desmoid tumors.

    • What is the primary focus of SpringWorks Therapeutics as a biopharmaceutical company?

      SpringWorks is focused on developing treatments for severe rare diseases and cancers through a precision medicine approach.

    Recent Analyst Ratings for
    $SWTX

    DatePrice TargetRatingAnalyst
    11/20/2024$60.00Outperform
    Evercore ISI
    2/5/2024$75.00Buy
    Guggenheim
    12/1/2022$45.00Buy
    BofA Securities
    9/8/2021$97.00 → $105.00Overweight
    JP Morgan
    8/5/2021$136.00 → $137.00Buy
    HC Wainwright & Co.
    More analyst ratings